What are the possible causes of a large difference between Transfer Lung Capacity for Carbon Monoxide (TLCO) and Carbon Monoxide Transfer Coefficient (KCO)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 6, 2025 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Causes of Large Differences Between TLCO and KCO

A large difference between Transfer Lung Capacity for Carbon Monoxide (TLCO) and Carbon Monoxide Transfer Coefficient (KCO) primarily indicates pathophysiological changes affecting either gas exchange surface area or lung volume distribution, with specific patterns pointing to distinct underlying conditions.

Understanding the Relationship Between TLCO and KCO

TLCO (also known as DLCO) is the product of two primary measurements:

  • KCO (transfer coefficient)
  • VA (alveolar volume)

Therefore: TLCO = KCO × VA 1

This relationship is fundamental to interpreting discrepancies between these values.

Major Causes of TLCO-KCO Discrepancies

1. Extrapulmonary Restriction

  • Pattern: Low TLCO, High KCO (often >120% predicted)
  • Mechanism: Inability to achieve full lung distension despite normal alveolar-capillary membrane 2, 3
  • Examples:
    • Respiratory muscle weakness
    • Pleural disease
    • Rib cage abnormalities
    • Obesity

2. Emphysema

  • Pattern: Low TLCO, Low or Normal KCO
  • Mechanism: Loss of alveolar surface area with air trapping 1, 4
  • Characteristics: KCO better reflects emphysematous changes than TLCO alone 5

3. Interstitial Lung Disease (ILD)

  • Pattern: Low TLCO, Variable KCO (depends on disease stage)
  • Mechanism: Diffuse loss of alveolar units with thickened alveolar-capillary membrane 1, 6
  • Note: In early ILD, KCO may be normal while TLCO is reduced

4. Pulmonary Vascular Disorders

  • Pattern: Low TLCO, Low KCO
  • Mechanism: Reduced pulmonary capillary blood volume 1, 3
  • Examples:
    • Pulmonary hypertension
    • Pulmonary embolism
    • Primary pulmonary vascular diseases

5. Anemia

  • Pattern: Low TLCO, Low KCO
  • Mechanism: Reduced hemoglobin available for CO binding 1, 3
  • Note: Requires adjustment of TLCO for hemoglobin concentration

6. Lung Resection or Localized Lung Disease

  • Pattern: Low TLCO, High KCO
  • Mechanism: Redistribution of blood flow to remaining healthy lung tissue 3
  • Examples: Pneumonectomy, lobectomy

7. Airflow Obstruction with Maldistribution

  • Pattern: Low TLCO, Variable KCO (40-120% predicted)
  • Mechanism: Uneven distribution of inspired gas mixture during breath-hold time 7, 3
  • Note: Severity depends on degree of obstruction and distribution pattern

Clinical Interpretation Algorithm

  1. Measure both TLCO and KCO along with VA
  2. Calculate KCO as percentage of predicted (not just absolute value)
  3. Assess pattern:
    • If KCO > 120% predicted with low VA: Consider extrapulmonary restriction
    • If KCO < 80% predicted with low VA: Consider parenchymal or vascular disease
    • If KCO normal (80-120%) with low TLCO: Consider early ILD or discrete loss of alveolar units

Important Considerations

  • The relationship between DLCO and VA is not linear; as VA decreases, DLCO falls linearly but KCO increases 8
  • A seemingly "normal KCO" with low VA should be interpreted as abnormal gas transfer 6
  • Adjustments for hemoglobin and carboxyhemoglobin concentrations are essential for accurate interpretation 1
  • The same TLCO value may result from various combinations of KCO and VA, each suggesting different pathologies 3

Common Pitfalls to Avoid

  • Misinterpreting normal KCO: In restrictive disorders, KCO may be elevated or normal despite impaired gas exchange
  • Failing to adjust for hemoglobin: Can lead to misdiagnosis of diffusion impairment in anemic patients
  • Overlooking VA measurement: Essential for proper interpretation of TLCO/KCO discrepancies
  • Ignoring technical factors: Poor test technique can create artificial discrepancies between TLCO and KCO

By systematically evaluating the relationship between TLCO, KCO, and VA, clinicians can gain valuable insights into the underlying pathophysiology affecting gas exchange in various pulmonary conditions.

Related Questions

Does the carbon monoxide transfer coefficient (KCO) correct for a submaximal inspiratory effort?
What is the interpretation of pulmonary function test results with DLCO uncorrected 70% predicted, DLCO corrected 67% predicted, alveolar volume (VA) 92% predicted, and KCO 72% predicted, and what further evaluation is recommended?
What does a low DLCO (Diffusing Capacity of the Lung for Carbon Monoxide)/VA (Alveolar Volume) ratio indicate and how is it managed?
Given a patient with DLCO (uncorrected) 72% predicted, DLCO (corrected) 67% predicted, DL/VA 64% predicted, alveolar volume (VA) 103% predicted, slow vital capacity (SVC) 94% predicted, inspiratory capacity (IC) 70% predicted, and total lung capacity (TLC) 127% predicted, what is the most likely diagnosis and appropriate treatment plan?
How should I interpret DLCO values and determine when to obtain a high‑resolution computed tomography scan in a patient being screened for interstitial lung disease (e.g., due to connective‑tissue disease, occupational or environmental exposure, or prior thoracic radiation)?
Can Paxil (paroxetine) cause weight gain?
At what age should women start getting pap (Papanicolau) smears and how often should they be screened?
What is the differential diagnosis for chronic severe pharyngodynia in an elderly male?
What is the management approach for a patient with elevated Luteinizing Hormone (LH) levels, normal Follicle-Stimulating Hormone (FSH) levels, and normal free and total Testosterone levels?
What is the treatment approach for osteoporosis patients with elevated C (carboxy-terminal) telopeptide levels?
Should Chronic Kidney Disease (CKD) stage 3B patients be on Farxiga (dapagliflozin) and Saxagliptin?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.